Early Phase 1 Schizophrenia Trial, Recruiting NCT04366518 Sponsor: Yale University Condition: Schizophrenia
Back to Schizophrenia

Early Phase 1 Schizophrenia Trial, Recruiting

NCT04366518
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old
  • You speak English
  • You are right-handed
  • You have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, schizotypal disorder, or brief psychotic disorder
  • You hear voices (auditory hallucinations) at least once a week

Who may not be able to join:

  • You currently use or are dependent on drugs or substances (a drug test will be used to check this)
  • You have a neurological, medical, or developmental condition that is known to significantly affect thinking or memory
  • You have metal implants of any kind, a pacemaker, a history of accidents involving metal, or you feel very uncomfortable in small, enclosed spaces (claustrophobia), as these are safety concerns for MRI scanning
  • You have a history of seizures
  • You have a history of violent behaviour
  • You have a history of suicide attempts or suicidal behaviour
  • You are pregnant (a urine test will be used to check this)
  • You are currently taking part in another clinical research study that involves a treatment or intervention
  • You have a history of difficulty urinating (urinary retention)
  • You have a history of delirium (sudden severe confusion)
  • You are currently taking any medication that affects a brain chemical called acetylcholine (cholinergic or anticholinergic medications) (confirm with trial site)
  • You have a history of asthma, diabetes, or heart/cardiovascular disease
  • A heart tracing test (EKG/ECG) shows signs of cardiovascular disease
  • You have been taking a type of medication called dopamine-2 antagonists for less than 6 months (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Albert Powers, MD, PhD, Yale University

Phone: 203-974-7329

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
15 July 2021
Est. completion
1 August 2032

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of conditioned hallucinations exhibited during saline vs placebo administration

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov